The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
B cells are associated with survival and immunotherapy response in sarcoma
Open accessAbstract
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely3,4. To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8+ T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases. Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tertiary lymphoid structures (TLS) have recently emerged as biomarkers of response to ICT across several tumor types, including lung cancer, melanoma, RCC, sarcoma, and urothelial cancer (163-167).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [163]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, these findings were corroborated in translational studies of separate cohorts of patients with melanoma36 and sarcoma37 who were treated with ICB.”
From B cells and tertiary lymphoid structures promote immunotherapy response (2020) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, it was shown that gene expression profiles associated with a high density of B cells and the presence of tertiary lymphoid structures predicted response to pembrolizumab in soft tissue sarcoma [26].”
From Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial (2021) · cites this paper as [26]
In the citing paper
“in soft-tissue sarcomas, the presence of TLS enriched in B cells was associated with a better response to PD-1 blockade (Petitprez et al., 2020).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Petitprez et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Self-citationB cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationTertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Self-citationTawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Self-citationCD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Abeshouse, A., Adebamowo, C., Adebamowo, S. N., Akbani, R., Akeredolu, T., Ally, A., Anderson, M. L., Anur, P., Appelbaum, E. L., Armenia, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.014 · Cited by 1,069
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Tertiary lymphoid structures in cancer and beyond
Dieu-Nosjean, M.-C., Goc, J., Giraldo, N. A., Sautès-Fridman, C., & Fridman, W. H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.006 · Cited by 617
Self-citation
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationTertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Self-citationHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationThe immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Metadata
- Authors
- Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., Moreira, M., Lacroix, G., Natario, I., Adam, J., Lucchesi, C., Laizet, Y., Toulmonde, M., Burgess, M. A., Bolejack, V., Reinke, D., Wani, K. M., Wang, W.-L., Lazar, A. J., Roland, C. L., Wargo, J. A., Italiano, A., Sautès-Fridman, C., Tawbi, H. A., & Fridman, W. H.
- Affiliations
- Inserm (FR)
- The University of Texas MD Anderson Cancer Center (US)
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
- Institut Gustave Roussy (FR)
- Institut Bergonié (FR)
- University of Pittsburgh (US)
- Cancer Research And Biostatistics (US)
- Sarcoma Alliance for Research through Collaboration (US)
- Corresponding author
- Tawbi, Hussein A.
- Fridman, Wolf H.
- ORCID
- Petitprez, Florent
- Keung, Emily Z.
- Chen, Tom Wei-Wu
- Sun, Cheng-Ming
- Jeng, Yung-Ming
- Moreira, Marco
- Lacroix, Guillaume
- Adam, Julien
- Lucchesi, Carlo
- Laizet, Yec′han
- Toulmonde, Maud
- Burgess, Melissa A.
- Bolejack, Vanessa
- Reinke, Denise
- Wang, Wei-Lien
- Lazar, Alexander J.
- Roland, Christina L.
- Wargo, Jennifer A.
- Tawbi, Hussein A.
- Fridman, Wolf H.
- Venue
- Nature
- Published
- 2020-01-15
- Volume
- 577
- Issue
- 7791
- Pages
- 556-560
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3000282923
- Cited by
- 1,942
- References
- 40
- Citations by year
- 2026: 215 · 2025: 257 · 2024: 304 · 2023: 308 · 2022: 330 · 2021: 335 · 2020: 189
- FWCI
- 167.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Institut National de la Santé et de la Recherche Médicale (UMRS1138)
- National Taiwan University Hospital
- Institut National Du Cancer
- National Taiwan University
- Sorbonne Université
- Université de Paris
- National Institutes of Health (T32CA0095999)
- University of Texas MD Anderson Cancer Center
- Labex Immuno-Oncology (LAXE62_9UMRS972 FRIDMAN, LAXE62_9UMRS972)
- National Cancer Institute (T32CA009599, K12CA088084)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- soft tissue sarcoma, B cells, tertiary lymphoid structures, tumor microenvironment, immune checkpoint blockade, pembrolizumab, anti-PD-1 therapy, immunotherapy response, prognostic factors, gene expression profiling, follicular dendritic cells, CD8+ T cells, survival
- MeSH terms
- Tertiary Lymphoid Structures, B-Lymphocytes, Humans, Immunotherapy, Mutation, Phenotype, Prognosis, Sarcoma, Reproducibility of Results, Cohort Studies, Survival Rate, CD8-Positive T-Lymphocytes, Dendritic Cells, Follicular, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B cells are associated with survival and immunotherapy response in sarcoma. https://app.cochat.ai/papers/10.1038/s41586-019-1906-8
- The paper
- Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., Moreira, M., Lacroix, G., Natario, I., Adam, J., Lucchesi, C., Laizet, Y., Toulmonde, M., Burgess, M. A., Bolejack, V., . . . Fridman, W. H. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature. https://doi.org/10.1038/s41586-019-1906-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.